Gyre Therapeutics, Inc. (GYRE)
GYRE Stock Price Chart
Explore Gyre Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GYRE price movements and trends.
GYRE Company Profile
Discover essential business fundamentals and corporate details for Gyre Therapeutics, Inc. (GYRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Apr 2006
Employees
579.00
Website
https://www.gyretx.comCEO
Ping Zhang
Description
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
GYRE Financial Timeline
Browse a chronological timeline of Gyre Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.08, while revenue estimate is $26.49m.
Earnings released on 7 May 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $22.52m , missing expectations by -28.75%.
Earnings released on 12 Mar 2026
EPS came in at $0.04 falling short of the estimated $0.06 by -29.42%, while revenue for the quarter reached $37.20m , beating expectations by +4.97%.
Earnings released on 7 Nov 2025
EPS came in at $0.06 surpassing the estimated $0.05 by +20.00%, while revenue for the quarter reached $30.56m , missing expectations by -15.81%.
Earnings released on 11 Aug 2025
EPS came in at $0.02 falling short of the estimated $0.03 by -33.33%, while revenue for the quarter reached $26.77m , missing expectations by -21.95%.
Earnings released on 9 May 2025
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $22.06m , missing expectations by -23.14%.
Earnings released on 17 Mar 2025
EPS came in at $0.01 falling short of the estimated $0.04 by -75.00%, while revenue for the quarter reached $27.87m , beating expectations by +18.60%.
Earnings released on 13 Nov 2024
EPS came in at $0.02 , while revenue for the quarter reached $25.49m .
Earnings released on 13 Aug 2024
EPS came in at $0.01 , while revenue for the quarter reached $25.23m , missing expectations by -77.77%.
Earnings released on 9 May 2024
EPS came in at $0.04 , while revenue for the quarter reached $27.17m .
Earnings released on 26 Mar 2024
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.57%, while revenue for the quarter reached $29.98m .
Stock split effective on 31 Oct 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Oct 2023
EPS came in at -$1.05 falling short of the estimated -$0.75 by -40.00%, while revenue for the quarter reached $30.74m .
Earnings released on 14 Aug 2023
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $26.14m .
Earnings released on 15 May 2023
EPS came in at $0.14 surpassing the estimated -$1.05 by +113.47%, while revenue for the quarter reached $24.44m .
Earnings released on 30 Mar 2023
EPS came in at -$0.05 surpassing the estimated -$1.58 by +96.53%, while revenue for the quarter reached $794.00k , beating expectations by +98.50%.
Dividend declared on 13 Jan 2023
A dividend of $0.24 per share was announced, adjusted to $3.60.
Earnings released on 14 Nov 2022
EPS came in at -$0.05 surpassing the estimated -$1.50 by +96.35%, while revenue for the quarter reached $29.17m .
Dividend declared on 21 Sept 2022
A dividend of $1.43 per share was announced, adjusted to $21.45.
Earnings released on 15 Aug 2022
EPS came in at $0.08 surpassing the estimated -$3.68 by +102.06%, while revenue for the quarter reached $23.33m .
Earnings released on 9 May 2022
EPS came in at $0.08 , while revenue for the quarter reached $794.00k .
Earnings released on 31 Mar 2022
EPS came in at -$0.65 surpassing the estimated -$6.85 by +90.55%, while revenue for the quarter reached $2.44m , beating expectations by +206.15%.
Earnings released on 12 Nov 2021
EPS came in at -$0.80 , while revenue for the quarter reached $2.30m .
Earnings released on 5 Aug 2021
EPS came in at -$0.64 , while revenue for the quarter reached $1.13m .
GYRE Stock Performance
Access detailed GYRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
